Study S001518

The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06058585
Acronym: CAPTIVATE
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 2000
Start: 2024-09-04
Primary completion: 2029-12-31
Lead sponsor: The George Institute
Conditions: Chronic Kidney Diseases
Interventions: DRUG:Finerenone; DRUG:Placebo Finerenone; DRUG:Semaglutide; DRUG:Placebo semaglutide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1324-3113

Registered primary outcomes

Core Primary Outcome Measure [From randomisation to week 108]
MRA Domain Primary Outcome Measure [From week 4 to week 108]
GLP1-RA Domain Primary Outcome Measure [From week 0 to week 108]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0002627	A Framework for Risk-Based Implementation of Combination Therapy in CKD: Who, Why, When, and How? Yeung EK, Clinical journal of the American Society of Nephrology : CJASN	2026	Randomized trial	PMID 42335037 DOI	cites ClinicalTrials.gov:NCT06058585; registry reference DERIVED:42335037
R0005745	A Dose of Perspective: A Multinational Survey of Patient and Clinician Views on Combination Therapy in CKD. Shah NA, Kidney360	2026	Nonrandomized study	PMID 42228487 DOI	cites ClinicalTrials.gov:NCT06058585; registry reference DERIVED:42228487